Online Resources for:

Evaluation of the cross-reactivity of antidrug antibodies to CT-P13 and infliximab reference product (Remicade): an analysis using immunoassays tagged with both agents

Walter Reinisch, Jørgen Jahnsen, Stefan Schreiber, Silvio Danese, Julián Panés, Alejandro Balsa, Won Park, JiSoo Kim, JeeUn Lee, Dae Hyun Yoo

Corresponding author: Professor Dae Hyun Yoo

Division of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea. Email: dhyoo@hanyang.ac.kr

Journal: BioDrugs

Online resource 1. Baseline patient characteristics for the PLANETAS safety population (patients with ankylosing spondylitis)

Characteristic*	CT-P13 5 mg/kg (n=128)	RP 5 mg/kg (n=122)	Total (N=250)
Age, years	38.0 (18–69)	38.0 (18–66)	38.0 (18–69)
Gender, no. (%)			
Male	102 (79.7)	100 (82.0)	202 (80.8)
Female	26 (20.3)	22 (18.0)	48 (19.2)
Ethnicity, no. (%)			
White	98 (76.6)	91 (74.6)	189 (75.6)
Asian	16 (12.5)	13 (10.7)	29 (11.6)
Other	14 (10.9)	18 (14.8)	32 (12.8)
Height, cm	172.0 (148–198)	171.0 (147–193)	172.0 (147–198)
Weight, kg	73.00 (45.0–120.0)	75.70 (45.5–122.7)	73.75 (45.0–122.7)
Body mass index, kg/m^2	24.41 (18.0–38.7)	25.59 (17.5–42.0)	25.12 (17.5–42.0)
Baseline BASDAI score, no. (%)			
<8	94 (73.4)	93 (76.2)	187 (74.8)
≥8	34 (26.6)	29 (23.8)	63 (25.2)
Screening BASDAI score, no. (%)			
<8	99 (77.3)	95 (77.9)	194 (77.6)
≥8	29 (22.7)	27 (22.1)	56 (22.4)

*Except where indicated otherwise, values are the median (minimum–maximum).

BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; RP, reference product.

Online resource 2. Agreement of immunogenicity testing between Assay ADA-A and Assay ADA-B[a] in PLANETAS (safety population)

Visit	Assay ADA-B outcome	Assay ADA-A outcome		PPA[b] (%)	NPA[c] (%)	Cohen's κ (95% CI)	p-value
		Pos	Neg				
All patients (N=250)[d]							
Screening	Pos	2	2	66.67	99.18	0.57 (0.12–1.00)	<0.001
	Neg	1	242				
Week 14	Pos	23	0	95.83	100.00	0.98 (0.93–1.00)	<0.001
	Neg	1	215				
Week 30	Pos	54	1	94.74	99.42	0.95 (0.91–1.00)	<0.001
	Neg	3	170				
Week 54	Pos	51	0	96.23	100.00	0.97 (0.94–1.00)	<0.001
	Neg	2	161				
EOS	Pos	69	1	87.34	99.36	0.89 (0.83–0.95)	<0.001
	Neg	10	155				
CT-P13 treatment group (N=128)[d]							
Screening	Pos	1	1	50.00	99.20	0.49 (-0.11–1.00)	<0.001
	Neg	1	124				
Week 14	Pos	10	0	90.91	100.00	0.95 (0.85–1.00)	<0.001
	Neg	1	110				
Week 30	Pos	30	1	93.75	98.82	0.93 (0.86–1.00)	<0.001
	Neg	2	84				
Week 54	Pos	25	0	100.00	100.00	1.00 (1.00–1.00)	<0.001
	Neg	0	84				
EOS	Pos	38	0	86.36	100.00	0.89 (0.80–0.98)	<0.001
	Neg	6	78				
RP treatment group (N=122)[d]							
Screening	Pos	1	1	100.00	99.16	0.66 (0.04–1.00)	<0.001
	Neg	0	118				
Week 14	Pos	13	0	100.00	100.00	1.00 (1.00–1.00)	<0.001
	Neg	0	105				
Week 30	Pos	24	0	96.00	100.00	0.97 (0.92–1.00)	<0.001
	Neg	1	86				
Week 54	Pos	26	0	92.86	100.00	0.95 (0.88–1.00)	<0.001
	Neg	2	77				
EOS	Pos	31	1	88.57	98.72	0.89 (0.80–0.98)	<0.001
	Neg	4	77				

[a]Assay ADA-A = ADA detection immunoassay with EU-approved Remicade tag; Assay ADA-B = ADA detection immunoassay with CT-P13 tag. [b]PPA = (number of patients with positive outcome for both Assay ADA-A and Assay ADA-B)/(number of patients with positive outcome for Assay ADA-A)*100. [c]NPA = (number of patients with negative outcome for both Assay ADA-A and Assay ADA-B)/(number of patients with negative outcome for Assay ADA-A)*100. [d]Concordance values will not reflect total patient numbers due to patients not being available for sampling or withdrawals throughout the study.

ADA, antidrug antibody; CI, confidence interval; EOS, end of study; EU, European Union; Neg, negative result; NPA, negative percentage agreement; Pos, positive result; PPA, positive percentage agreement; RP, reference product.

Online resource 3. Agreement of immunogenicity testing between Assay NAb-A and Assay NAb-B[a] in PLANETAS (safety population)

Visit	Assay NAb-B outcome	Assay NAb-A outcome			PPA[b] (%)	NPA[c] (%)	Cohen's κ (95% CI)	p-value
		Pos	Neg[d]	QNS[e]				
All patients (N=250)[f]								
Screening	Pos	0	1	0	0.00	99.59	-0.01 (-0.01–0.00)	0.928
	Neg[d]	2	244	0				
	QNS	0	0	0	-	-	-	-
Week 14	Pos	22	0	1	95.65	100.00	0.98 (0.93–1.00)	<0.001
	Neg	1	215	0				
	QNS	0	0	0	-	-	-	-
Week 30	Pos	52	2	1	94.55	98.84	0.94 (0.89–0.99)	<0.001
	Neg	3	170	0				
	QNS	0	0	0	-	-	-	-
Week 54	Pos	51	0	0	96.23	100.00	0.97 (0.94–1.00)	<0.001
	Neg	2	161	0				
	QNS	0	0	0	-	-	-	-
EOS	Pos	66	2	0	84.62	98.73	0.86 (0.79–0.93)	<0.001
	Neg	12	155	0				
	QNS	0	0	0	-	-	-	-
CT-P13 treatment group (N=128)[f]								
Screening	Pos	0	1	0	0.00	99.21	-0.01 (-0.02–0.00)	0.929
	Neg	1	125	0				
	QNS	0	0	0	-	-	-	-
Week 14	Pos	9	0	1	90.00	100.00	0.94 (0.83–1.00)	<0.001
	Neg	1	110	0				
	QNS	0	0	0	-	-	-	-
Week 30	Pos	29	1	1	93.55	98.82	0.93 (0.86–1.00)	<0.001
	Neg	2	84	0				
	QNS	0	0	0	-	-	-	-
Week 54	Pos	25	0	0	100.00	100.00	1.00 (1.00–1.00)	<0.001
	Neg	0	84	0				
	QNS	0	0	0	-	-	-	-
EOS	Pos	35	1	0	81.40	98.73	0.83 (0.73–0.94)	<0.001
	Neg	8	78	0				
	QNS	0	0	0	-	-	-	-
RP treatment group (N=122)[f]								
Screening	Pos	0	0	0	0.00	100.00	NE (NE–NE)	NE
	Neg[d]	1	119	0				
	QNS	0	0	0	-	-	-	-
Week 14	Pos	13	0	0	100.00	100.00	1.00 (1.00–1.00)	<0.001
	Neg	0	105	0				
	QNS	0	0	0	-	-	-	-
Week 30	Pos	23	1	0	95.83	98.85	0.95 (0.87–1.00)	<0.001
	Neg	1	86	0				
	QNS	0	0	0	-	-	-	-
Week 54	Pos	26	0	0	92.86	100.00	0.95 (0.88–1.00)	<0.001

	Neg	2	77	0				
	QNS	0	0	0	-	-	-	-
EOS	Pos	31	1	0	88.57	98.72	0.89 (0.80–0.98)	<0.001
	Neg	4	77	0				
	QNS	0	0	0	-	-	-	-

[a]Assay NAb-A = NAb detection immunoassay with EU-approved Remicade tag; Assay NAb-B = NAb detection immunoassay with CT-P13 tag. [b]PPA = (number of patients with positive outcome for both Assay NAb-A and Assay NAb-B)/(number of patients with positive outcome for Assay NAb-A)*100. [c]NPA = (number of patients with negative outcome for both Assay NAb-A and Assay NAb-B)/(number of patients with negative outcome for Assay NAb-A)*100. [d]The NAb-negative population constitutes both 1) patients who were originally tested for ADA and were found to be negative (and therefore, not further tested for NAb) and 2) patients who originally tested positive for ADA but were subsequently found to be negative for NAb. [e]Counts of QNS are for information purposes only and not used in calculation of PPA, NPA or Cohen's κ. [f]Concordance values will not reflect total patient numbers due to patients not being available for sampling or withdrawals throughout the study.

ADA, antidrug antibody; CI, confidence interval; EOS, end of study; EU, European Union; NAb, neutralising antibody; NE, not estimable; Neg, negative result; NPA, negative percentage agreement; Pos, positive result; PPA, positive percentage agreement; QNS, quantity not sufficient; RP, reference product.

Online resource 4. Baseline patient characteristics for the PLANETRA safety population (patients with rheumatoid arthritis)

Characteristic*	CT-P13 3 mg/kg (n=302)	RP 3 mg/kg (n=300)	Total (N=602)
Age, years	50 (18–75)	50 (21–74)	50 (18–75)
Gender, no. (%)			
Female	245 (81.1)	252 (84.0)	497 (82.6)
Male	57 (18.9)	48 (16.0)	105 (17.4)
Ethnicity, no. (%)			
Asian	34 (11.3)	36 (12.0)	70 (11.6)
Black	2 (0.7)	1 (0.3)	3 (0.5)
White	220 (72.8)	219 (73.0)	439 (72.9)
Other	46 (15.2)	44 (14.7)	90 (15.0)
Height (cm)	162.0 (144.0–186.0)	162.0 (124.0–190.0)	162.0 (124.0–190.0)
Weight (kg)	69.0 (36.5–134.0)	68.0 (36.0–136.0)	68.75 (36.0–136.0)
Body mass index (kg/m^2)	26.32 (13.9–49.8)	25.33 (15.0–53.1)	25.85 (13.9–53.1)
Baseline serum CRP concentration, no. (%)			
≤2mg/ dL	162 (53.6)	164 (54.7)	326 (54.2)
>2mg/ dL	140 (46.4)	136 (45.3)	276 (45.8)
Screening serum CRP concentration, no. (%)			
≤2mg/ dL	196 (64.9)	202 (67.3)	398 (66.1)
>2mg/ dL	105 (34.8)	98 (32.7)	203 (33.7)

*Except where indicated otherwise, values are the median (minimum–maximum).

CRP, C-reactive protein; RP, reference product.

Online resource 5. Agreement of immunogenicity testing between Assay ADA-A and Assay ADA-B[a] in PLANETRA (safety population)

Visit	Assay ADA-B outcome	Assay ADA-A outcome			PPA[b] (%)	NPA[c] (%)	Cohen's κ (95% CI)	p-value
		Pos	Neg	Missing[d]				
All patients (N=602)[e]								
Screening	Pos	15	4	0	100.00	99.32	0.88 (0.76–1.00)	<0.001
	Neg	0	580	0				
	Missing[d]	0	0	0	-	-	-	-
Week 14	Pos	134	8	0	97.10	98.01	0.94 (0.91–0.97)	<0.001
	Neg	4	395	0				
	Missing	1	1	0	-	-	-	-
Week 30	Pos	238	8	0	97.54	96.93	0.94 (0.92–0.97)	<0.001
	Neg	6	253	0				
	Missing	0	0	0	-	-	-	-
Week 54	Pos	220	7	0	94.83	96.86	0.92 (0.88–0.95)	<0.001
	Neg	12	216	0				
	Missing	0	0	0	-	-	-	-
EOS	Pos	292	3	1	94.50	98.69	0.92 (0.89–0.96)	<0.001
	Neg	17	226	0				
	Missing	0	0	0	-	-	-	-
CT-P13 treatment group (N=302)[e]								
Screening	Pos	9	3	0	100.00	98.97	0.85 (0.69–1.00)	<0.001
	Neg	0	289	0				
	Missing	0	0	0	-	-	-	-
Week 14	Pos	68	4	0	98.55	98.02	0.95 (0.91–0.99)	<0.001
	Neg	1	198	0				
	Missing	0	1	0	-	-	-	-
Week 30	Pos	120	6	0	98.36	95.38	0.94 (0.89–0.98)	<0.001
	Neg	2	124	0				
	Missing	0	0	0	-	-	-	-
Week 54	Pos	120	5	0	96.77	95.58	0.92 (0.88–0.97)	<0.001
	Neg	4	108	0				
	Missing	0	0	0	-	-	-	-
EOS	Pos	150	1	1	94.94	99.10	0.93 (0.89–0.98)	<0.001
	Neg	8	110	0				
	Missing	0	0	0	-	-	-	-
RP treatment group (N=300)[e]								
Screening	Pos	6	1	0	100.00	99.66	0.92 (0.77–1.00)	<0.001
	Neg	0	291	0				
	Missing	0	0	0	-	-	-	-
Week 14	Pos	66	4	0	95.65	98.01	0.93 (0.88–0.98)	<0.001
	Neg	3	197	0				
	Missing	1	0	0	-	-	-	-
Week 30	Pos	118	2	0	96.72	98.47	0.95 (0.91–0.99)	<0.001
	Neg	4	129	0				
	Missing	0	0	0	-	-	-	-
Week 54	Pos	100	2	0	92.59	98.18	0.91 (0.85–0.96)	<0.001

	Neg	8	108	0				
	Missing	0	0	0	-	-	-	-
EOS	Pos	142	2	0	94.04	98.31	0.92 (0.87–0.97)	<0.001
	Neg	9	116	0				
	Missing	0	0	0	-	-	-	-

[a]Assay ADA-A = ADA detection immunoassay with EU-approved Remicade tag; Assay ADA-B = ADA detection immunoassay with CT-P13 tag. [b]PPA = (number of patients with positive outcome for both Assay ADA-A and Assay ADA-B)/(number of patients with positive outcome for Assay ADA-A)*100. [c]NPA = (number of patients with negative outcome for both Assay ADA-A and Assay ADA-B)/(number of patients with negative outcome for Assay ADA-A)*100. [d]Counts of missing values are for information purposes only, are not used in calculations of PPA, NPA or κ and include patients with a QNS outcome. [e]Concordance values will not reflect total patient numbers due to patients not being available for sampling or withdrawals throughout the study.

ADA, antidrug antibody; CI, confidence interval; EOS, end of study; EU, European Union; Neg, negative result; NPA, negative percentage agreement; Pos, positive result; PPA, positive percentage agreement; QNS, quantity not sufficient; RP, reference product.

Online resource 6. Agreement of immunogenicity testing between Assay NAb-A and Assay NAb-B[a] in PLANETRA (safety population)

Visit	Assay NAb-B outcome	Assay NAb-A outcome			PPA[b] (%)	NPA[c] (%)	Cohen's κ (95% CI)	p-value
		Pos	Neg[d]	Missing[e]				
All patients (N=602)[f]								
Screening	Pos	3	2	0	60.00	99.66	0.60 (0.24–0.96)	<0.001
	Neg	2	592	0				
	Missing[d]	0	0	0	-	-	-	-
Week 14	Pos	130	8	2	96.30	98.02	0.94 (0.90–0.97)	<0.001
	Neg	5	396	0				
	Missing	1	1	0	-	-	-	-
Week 30	Pos	234	8	0	96.30	96.95	0.93 (0.90–0.96)	<0.001
	Neg	9	254	0				
	Missing	0	0	0	-	-	-	-
Week 54	Pos	216	8	0	95.15	96.49	0.92 (0.88–0.95)	<0.001
	Neg	11	220	0				
	Missing	0	0	0	-	-	-	-
EOS	Pos	287	5	1	94.72	97.87	0.92 (0.89–0.95)	<0.001
	Neg	16	230	0				
	Missing	0	0	0	-	-	-	-
CT-P13 treatment group (N=302)[f]								
Screening	Pos	1	1	0	33.33	99.66	0.40 (-0.15–0.94)	<0.001
	Neg	2	297	0				
	Missing	0	0	0	-	-	-	-
Week 14	Pos	67	4	0	97.10	98.02	0.94 (0.90–0.99)	<0.001
	Neg	2	198	0				
	Missing	0	1	0	-	-	-	-
Week 30	Pos	117	6	0	96.69	95.42	0.92 (0.87–0.97)	<0.001
	Neg	4	125	0				
	Missing	0	0	0	-	-	-	-
Week 54	Pos	120	5	0	97.56	95.61	0.93 (0.89–0.98)	<0.001
	Neg	3	109	0				
	Missing	0	0	0	-	-	-	-
EOS	Pos	148	2	1	95.48	98.25	0.93 (0.89–0.98)	<0.001
	Neg	7	112	0				
	Missing	0	0	0	-	-	-	-
RP treatment group (N=300)[f]								
Screening	Pos	2	1	0	100.00	99.66	0.80 (0.41–1.00)	<0.001
	Neg	0	295	0				
	Missing	0	0	0	-	-	-	-
Week 14	Pos	63	4	2	95.45	98.02	0.93 (0.88–0.98)	<0.001
	Neg	3	198	0				
	Missing	1	0	0	-	-	-	-
Week 30	Pos	117	2	0	95.90	98.47	0.94 (0.90–0.99)	<0.001
	Neg	5	129	0				
	Missing	0	0	0	-	-	-	-

Week 54	Pos	96	3	0	92.31	97.37	0.90 (0.84–0.96)	<0.001
	Neg	8	111	0				
	Missing	0	0	0	-	-	-	-
EOS	Pos	139	3	0	93.92	97.52	0.91 (0.86–0.96)	<0.001
	Neg	9	118	0				
	Missing	0	0	0	-	-	-	-

[a]Assay NAb-A = NAb detection immunoassay with EU-approved Remicade tag; Assay NAb-B = NAb detection immunoassay with CT-P13 tag. [b]PPA = (number of patients with positive outcome for both Assay NAb-A and Assay NAb-B)/(number of patients with positive outcome for Assay NAb-A)*100. [c]NPA = (number of patients with negative outcome for both Assay NAb-A and Assay NAb-B)/(number of patients with negative outcome for Assay NAb-A)*100. [d]The NAb-negative population constitutes both 1) patients who were originally tested for ADA and were found to be negative (and therefore, not further tested for NAb) and 2) patients who originally tested positive for ADA but were subsequently found to be negative for NAb. [e]Counts of missing values are for information purposes only, are not used in calculations of PPA, NPA or κ and include patients with a QNS outcome. [f]Concordance values will not reflect total patient numbers due to patients not being available for sampling or withdrawals throughout the study.

ADA, antidrug antibody; CI, confidence interval; EOS, end of study; EU, European Union; NAb, neutralising antibody; Neg, negative result; NPA, negative percentage agreement; Pos, positive result; PPA, positive percentage agreement; QNS, quantity not sufficient; RP, reference product.

Online resource 7. Agreement of immunogenicity testing between Assay ADA-A and Assay ADA-B[a] in pooled analysis of PLANETAS and PLANETRA (safety populations)

Visit	Assay ADA-B outcome	Assay ADA-A outcome			PPA[b] (%)	NPA[c] (%)	Cohen's κ (95% CI)	p-value
		Pos	Neg	Missing[d]				
All patients (N=852)[e]								
Screening	Pos	17	6	0	94.44	99.28	0.83 (0.70–0.95)	<0.001
	Neg	1	822	0				
	Missing[d]	0	0	0	-	-	-	-
Week 14	Pos	157	8	0	96.91	98.71	0.95 (0.92–0.98)	<0.001
	Neg	5	610	0				
	Missing	1	1	0	-	-	-	-
Week 30	Pos	292	9	0	97.01	97.92	0.95 (0.93–0.97)	<0.001
	Neg	9	423	0				
	Missing	0	0	0	-	-	-	-
Week 54	Pos	271	7	0	95.09	98.18	0.94 (0.91–0.96)	<0.001
	Neg	14	377	0				
	Missing	0	0	0	-	-	-	-
EOS	Pos	361	4	1	93.04	98.96	0.92 (0.89–0.95)	<0.001
	Neg	27	381	0				
	Missing	0	0	0	-	-	-	-
CT-P13 group (N=430)[e]								
Screening	Pos	10	4	0	90.91	99.04	0.79 (0.62–0.97)	<0.001
	Neg	1	413	0				
	Missing	0	0	0	-	-	-	-
Week 14	Pos	78	4	0	97.50	98.72	0.95 (0.92–0.99)	<0.001
	Neg	2	308	0				
	Missing	0	1	0	-	-	-	-
Week 30	Pos	150	7	0	97.40	96.74	0.94 (0.90–0.97)	<0.001
	Neg	4	208	0				
	Missing	0	0	0	-	-	-	-
Week 54	Pos	145	5	0	97.32	97.46	0.95 (0.91–0.98)	<0.001
	Neg	4	192	0				
	Missing	0	0	0	-	-	-	-
EOS	Pos	188	1	1	93.07	99.47	0.92 (0.89–0.96)	<0.001
	Neg	14	188	0				
	Missing	0	0	0	-	-	-	-
RP treatment group (N=422)[e]								
Screening	Pos	7	2	0	100.00	99.51	0.87 (0.70–1.00)	<0.001
	Neg	0	409	0				
	Missing	0	0	0	-	-	-	-
Week 14	Pos	79	4	0	96.34	98.69	0.95 (0.91–0.99)	<0.001
	Neg	3	302	0				
	Missing	1	0	0	-	-	-	-
Week 30	Pos	142	2	0	96.60	99.08	0.96 (0.93–0.99)	<0.001
	Neg	5	215	0				
	Missing	0	0	0	-	-	-	-
Week 54	Pos	126	2	0	92.65	98.93	0.92 (0.88–0.97)	<0.001

	Neg	10	185	0				
	Missing	0	0	0	-	-	-	-
EOS	Pos	173	3	0	93.01	98.47	0.92 (0.88–0.96)	<0.001
	Neg	13	193	0				
	Missing	0	0	0	-	-	-	-

[a]Assay ADA-A = ADA detection immunoassay with EU-approved Remicade tag; Assay ADA-B = ADA detection immunoassay with CT-P13 tag. [b]PPA = (number of patients with positive outcome for both Assay ADA-A and Assay ADA-B)/(number of patients with positive outcome for Assay ADA-A)*100. [c]NPA = (number of patients with negative outcome for both Assay ADA-A and Assay ADA-B)/(number of patients with negative outcome for Assay ADA-A)*100. [d]Counts of missing values are for information purposes only, are not used in calculations of PPA, NPA or κ and include patients with a QNS outcome. [e]Concordance values will not reflect total patient numbers due to patients not being available for sampling or withdrawals throughout the study.

ADA, antidrug antibody; CI, confidence interval; EOS, end of study; EU, European Union; Neg, negative result; NPA, negative percentage agreement; Pos, positive result; PPA, positive percentage agreement; QNS, quantity not sufficient; RP, reference product.

Online resource 8. Agreement of immunogenicity testing between Assay NAb-A and NAb-B[a] in pooled analysis of PLANETAS and PLANETRA (safety populations)

Visit	Assay NAb-B outcome	Assay NAb-A outcome			PPA[b] (%)	NPA[c] (%)	Cohen's κ (95% CI)	p-value
		Pos	Neg[d]	Missing[e]				
All patients (N=852)[f]								
Screening	Pos	3	3	0	42.86	99.64	0.46 (0.12–0.80)	<0.001
	Neg	4	836	0				
	Missing[e]	0	0	0	-	-	-	-
Week 14	Pos	152	8	3	96.20	98.71	0.94 (0.92–0.97)	<0.001
	Neg	6	611	0				
	Missing	1	1	0	-	-	-	-
Week 30	Pos	286	10	1	95.97	97.70	0.94 (0.91–0.96)	<0.001
	Neg	12	424	0				
	Missing	0	0	0	-	-	-	-
Week 54	Pos	267	8	0	95.36	97.94	0.94 (0.91–0.96)	<0.001
	Neg	13	381	0				
	Missing	0	0	0	-	-	-	-
EOS	Pos	353	7	1	92.65	98.21	0.91 (0.88–0.94)	<0.001
	Neg	28	385	0				
	Missing	0	0	0	-	-	-	-
CT-P13 treatment group (N=430)[f]								
Screening	Pos	1	2	0	25.00	99.53	0.28 (-0.16–0.72)	<0.001
	Neg	3	422	0				
	Missing	0	0	0	-	-	-	-
Week 14	Pos	76	4	1	96.20	98.72	0.94 (0.90–0.99)	<0.001
	Neg	3	308	0				
	Missing	0	1	0	-	-	-	-
Week 30	Pos	146	7	1	96.05	96.76	0.93 (0.89–0.97)	<0.001
	Neg	6	209	0				
	Missing	0	0	0	-	-	-	-
Week 54	Pos	145	5	0	97.97	97.47	0.95 (0.92–0.99)	<0.001
	Neg	3	193	0				
	Missing	0	0	0	-	-	-	-
EOS	Pos	183	3	1	92.42	98.45	0.91 (0.87–0.95)	<0.001
	Neg	15	190	0				
	Missing	0	0	0	-	-	-	-
RP treatment group (N=422)[f]								
Screening	Pos	2	1	0	66.67	99.76	0.66 (0.23–1.00)	<0.001
	Neg	1	414	0				
	Missing	0	0	0	-	-	-	-
Week 14	Pos	76	4	2	96.20	98.70	0.94 (0.90–0.99)	<0.001
	Neg	3	303	0				
	Missing	1	0	0	-	-	-	-
Week 30	Pos	140	3	0	95.89	98.62	0.95 (0.92–0.98)	<0.001
	Neg	6	215	0				

	Missing	0	0	0	-	-	-	-
Week 54	Pos	122	3	0	92.42	98.43	0.92 (0.87–0.96)	<0.001
	Neg	10	188	0				
	Missing	0	0	0	-	-	-	-
EOS	Pos	170	4	0	92.90	97.99	0.91 (0.87–0.95)	<0.001
	Neg	13	195	0				
	Missing	0	0	0				-

[a]Assay NAb-A = NAb detection immunoassay with EU-approved Remicade tag; Assay NAb-B = NAb detection immunoassay with CT-P13 tag. [b]PPA = (number of patients with positive outcome for both Assay NAb-A and Assay NAb-B)/(number of patients with positive outcome for Assay NAb-A)*100. [c]NPA = (number of patients with negative outcome for both Assay NAb-A and Assay NAb-B)/(number of patients with negative outcome for Assay NAb-A)*100. [d]The NAb-negative population constitutes both 1) patients who were originally tested for ADA and were found to be negative (and therefore, not further tested for NAb) and 2) patients who originally tested positive for ADA but were subsequently found negative for NAb. [e]Counts of missing values are for information purposes only, are not used in calculations of PPA, NPA or κ and include patients with a QNS. [f]Concordance values will not reflect total patient numbers due to patients not being available for sampling or withdrawals throughout the study.

ADA, antidrug antibody; CI, confidence interval; EOS, end of study; EU, European Union; NAb, neutralising antibody; Neg, negative result; NPA, negative percentage agreement; Pos, positive result; PPA, positive percentage agreement; QNS, quantity not sufficient; RP, reference product.